REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo for tough myeloma shows early promise but study ends early
Disease control TerminatedThis early-phase trial tested a new drug (CB-839 HCl) combined with two standard treatments (carfilzomib and dexamethasone) in 19 adults with multiple myeloma that had come back or stopped responding to prior therapy. The goal was to find the safest dose and check for side effect…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:23 UTC
-
New combo therapy for tough myeloma cases shows early promise but study halted
Disease control TerminatedThis early-phase study tested a new drug (KRT-232) combined with three standard myeloma treatments in 35 patients whose cancer had come back or stopped responding. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limi…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
Experimental CAR t therapy for myeloma shows early promise but trial halted
Disease control TerminatedThis early-phase study tested a new treatment called Descartes-15 for people with multiple myeloma that had come back or stopped responding to other therapies. The treatment uses a patient's own immune cells, engineered with RNA to target cancer cells. Only 4 people were enrolled…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:39 UTC